Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive quetiapine versus adjunctive haloperidol with sodium valproate for acute mania or mixed episodes in bipolar I disorder
IRCT20150221021168N3Phase 3Completed
- Sponsor
- University of Social Welfare and Rehabilitation Sciences
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of quetiapine, haloperidol and valproic acid in bipolar I disorder (2 arms), sponsored by University of Social Welfare and Rehabilitation Sciences. Primary endpoints: Duration of signs and symptoms of active phase, Intensity of signs and symptoms of active phase and 1 more. Started May 2021; status: completed.
02
Drugs
quetiapinehaloperidolvalproic acid
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on IRCT20150221021168N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150221021168N3.